FDA Approves Auvelity for Agitation in Alzheimer’s Disease - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Approves Auvelity for Agitation in Alzheimer’s Disease

The oral combination therapy expands treatment options for agitation associated with dementia due to Alzheimer’s disease.

  • By

  • Kathryn Wighton

  • April 30, 2026

  • 3 min

Share

Original Source(s)

FDA Approves Auvelity for Agitation in Alzheimer’s Disease

  • by Kathryn Wighton

  • April 30, 2026

Related Content

GLP-1 Drugs Tied to Lower Addiction Risk

In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.

Top 10 Evidence-Based Essentials in Neurology

A structured framework of guidelines, trials, therapies, and tools used in clinical practice.

Not All Poststroke Cognitive Patterns Plateau

Researchers identify divergent recovery, persistence, and decline patterns across cognitive domains following stroke.